Finance Watch: Mega-Rounds Balance Out Influx Of Smaller VC Deals
Average Deal Size Is Up But Falling As Investment Dips
Private Company Edition: The amount of venture capital investment in biopharma companies has shrunk from quarter to quarter, but the average deal size remained high until the third quarter. Larger rounds from Treeline, Odyssey and Neumora offset a plethora of smaller VC financings early in Q4.
You may also be interested in...
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
The Danish firm’s Q2 sales fell short of expectations due to poor rare disease and diabetes performance, but a potentially billion-dollar buy of Inversago stole attention as observers highlighted the historical risks of targeting the cannabinoid-1 receptor.
Neumora’s once-daily oral kappa opioid receptor (KOR) antagonist navacaprant succeeded in a Phase II trial and will move into the first of three Phase III studies soon, with a US filing targeted for 2025.